BRINGING INDUSTRY INTO THE FOLD

When Johnson & Johnson, Pfizer, and M Ventures (Merck’s venture arm) joined as investors in Nucleome’s Series A funding round, it wasn’t just about capital. It was a shared conviction that Nucleome’s 3D genomics platform could unlock a new genomics-led era in drug discovery.

OSE played a central role in forming and shaping those early relationships – helping Nucleome pair its breakthrough science with the strategic reach of global pharma leaders.

COMPLEMENTARY STRENGTHS

Nucleome brought to the table its proprietary technology, which combines 3D genome mapping with machine learning to show how specific genetic changes are linked to disease endotypes.

In return, pharma partners provide commercial insights and therapeutic expertise from the front line of drug development.

The company has already collaborated with one of these partners and obtained key insights, validating Nucleome’s technology and opening the door to further future global alliances.

SCALING IMPACT

Nucleome’s platform can be applied across a number of varied cell types. The company’s own pipeline is focused on inflammatory diseases, with the potential to expand indications through additional collaborations.

And as confidence grows in genetically guided drug development, Nucleome is at the forefront – progressing its pipeline, expanding partnerships, and preparing for a £50m+ Series B.

A MODEL FOR COLLABORATIVE INNOVATION

Nucleome’s journey underscores how academic brilliance can have real-world impact through strategic partnerships – validating science, accelerating pipelines, and attracting global investment.

It’s also a powerful example of what OSE was built to do: bring together exceptional science, visionary founders, and world-leading partners to build category-defining companies.

Unlocking the non-coding genome won’t happen in isolation. Nucleome proves it takes shared ambition and the right partners to transform potential into global impact.